3-氨基-5-甲基-1H-吡唑-4-甲腈 | 5453-07-6

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 亚胺内酰胺
• 中文名称: 3-氨基-5-甲基-1H-吡唑-4-甲腈
• 中文别名: 5-氨基-4-氰基-3-甲基吡唑
• 英文名称: 3-amino-5-methyl-1H-pyrazole-4-carbonitrile
• 英文别名: 5-amino-3-methyl-1H-pyrazole-4-carbonitrile
• CAS: 5453-07-6
• 化学式: C₅H₆N₄
• mdl: MFCD00128276
• 分子量: 122.129
• InChiKey: CRRHJAMDQMQGKG-UHFFFAOYSA-N

物化性质

• 熔点：
  162℃
• 沸点：
  429.4±45.0 °C(Predicted)
• 密度：
  1.32

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  78.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Amino-4-cyano-5-methylpyrazole
Synonyms: 3-Amino-5-methyl-1H-pyrazole-4-carbonitrile

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Amino-4-cyano-5-methylpyrazole
CAS number: 5453-07-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H6N4
Molecular weight: 122.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基-5-甲基-1H-吡唑-4-甲腈 生成 3-氨基-5-甲基-1H-吡唑-4-甲酰胺
  参考文献：
  名称：

  BONTEMS, ROGER J.;ANDERSON, JACK D.;SMEE, DONALD F.;JIN, AI;ALAGHAMANDAN,+, J. MED. CHEM., 33,(1990) N, C. 2174-2178

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(1-乙氧基亚乙基)丙二腈 在 一水合肼 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 生成 3-氨基-5-甲基-1H-吡唑-4-甲腈
  参考文献：
  名称：

  含氰基和氨基取代基的 NH-吡唑固态结构中氢键的相互作用

  摘要：

  摘要 通过固体化合物的 X 射线晶体学和 DFT B3LYP/6-31G** 研究了两个在 5(3) 位具有氢原子或甲基的 4-氰基-3(5)-氨基吡唑的环状互变异构平衡**和 CBS-QB3 计算自由分子。发现 3-氨基互变异构体是更适合游离分子的形式，并且是固态的唯一形式。

  DOI：

  10.1016/j.molstruc.2012.01.026

文献信息

• Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction
  申请人：Pfizer Inc.

  公开号：US06407114B1

  公开（公告）日：2002-06-18

  There is provided compounds of formula IA and of formula IB, wherein R1, R2, R3, R4 and A have meanings given in the description, which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.

  提供了式IA和式IB的化合物， 其中R1、R2、R3、R4和A的含义如描述中所示，在治疗和预防需要抑制环状鸟苷3′,5′-单磷酸酯酶（例如cGMP PDE5）的医疗状况中非常有用。
• Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists
  申请人：Clasby C. Martin

  公开号：US20060135526A1

  公开（公告）日：2006-06-22

  Compounds having the structural formula I are disclosed, wherein A is alkylene, or optionally substituted arylene, cycloalkylene or heteroaryldiyl; X is —C(O)— or —S(O) 2 —; R 1 is alkyl or cycloalkyl; R 2 is hydrogen, halo or —CN; R 3 is hydrogen or alkyl; R 4 is hydrogen, alkyl, alkoxy, hydroxyalkyl, aminoalkyl-, cycloalkyl, heterocycloalkyl, heterocycloalkyl substituted by alkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; or R 3 and R 4 , form an optionally substituted 5-7 membered ring, said ring optionally comprising an additional heteroatom ring member; R 7 is alkyl, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyl, halo, morpholinyl, optionally substituted piperazinyl, or optionally substituted azacycloalkyl. Also disclosed is the use of the compounds in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, pharmaceutical compositions comprising them and kits comprising the components of the combinations.

  揭示了具有结构式I的化合物，其中A是烷基，或者可选择地取代的芳基，环烷基或杂芳基二基；X是—C(O)—或—S(O)2—；R1是烷基或环烷基；R2是氢，卤素或—CN；R3是氢或烷基；R4是氢，烷基，烷氧基，羟基烷基，氨基烷基，环烷基，杂环烷基，被烷基取代的杂环烷基，可选择地取代的芳基烷基或可选择地取代的杂芳基烷基；或者R3和R4形成一个可选择地取代的5-7成员环，所述环可选择地包含一个额外的杂原子环成员；R7是烷基，可选择地取代的苯基，可选择地取代的杂芳基，环烷基，卤素，吗啉基，可选择地取代的哌嗪基，或可选择地取代的氮杂环烷基。还揭示了这些化合物在帕金森病治疗中的用途，单独或与其他治疗帕金森病的药剂组合使用，包含它们的药物组合物和包含组合物组分的工具包。
• 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY 한국화학연구원(319980077651)

  公开号：KR20180137057A

  公开（公告）日：2018-12-27

  본 발명은 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 접합 피리미딘 유도체는 브루톤 티로신 키나제 또는 TMD80의 활성을 억제하는 능력이 우수하므로, 브루톤 티로신 키나제 활성과 관련된 질환, 특히 암 또는 자가면역질환을 예방 또는 치료하는데 유용하게 사용할 수 있다.

  This is the translated text in Chinese: 本发明涉及连接嘧啶衍生物，其制备方法以及包含其作为有效成分的布鲁替罗辛酪氨酸激酶活性相关疾病的预防或治疗药物组合物。根据本发明，连接嘧啶衍生物具有优越的抑制布鲁替罗辛酪氨酸激酶或TMD80活性的能力，因此可以用于预防或治疗与布鲁替罗辛酪氨酸激酶活性相关的疾病，特别是癌症或自身免疫性疾病。
• [EN] PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE<br/>[FR] PIPÉRIDINYLPYRAZOLOPYRIMIDINONES ET LEUR UTILISATION
  申请人：BAYER PHARMA AG

  公开号：WO2016071216A1

  公开（公告）日：2016-05-12

  The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代哌啶基吡唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性止血障碍的患者的急性和复发性出血，其中出血与从重经期出血、产后出血、出血性休克、出血性膀胱炎、胃肠道出血、创伤、手术、移植、中风、肝脏疾病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤等一组疾病或医疗干预有关。
• [EN] ATG7 INHIBITORS AND THE USES THEREOF<br/>[FR] INHIBITEURS D'ATG7 ET LEURS UTILISATIONS
  申请人：MILLENNIUM PHARM INC

  公开号：WO2018089786A1

  公开（公告）日：2018-05-17

  Disclosed are chemical entities which are compounds of formula (I) : or a pharmaceutically acceptable salt thereof, wherein R1, R2, and Ra have the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer.

  本公开涉及化学实体，其为以下式（I）的化合物：或其药学上可接受的盐，其中R1、R2和Ra具有此处描述的值。根据本公开的化学实体可以用作ATG7的抑制剂。还提供了包括本公开的化学实体的药物组合物以及使用这些组合物治疗癌症的方法。